U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Global Sepsis Treatment Market Report: Growth, Expansion, and Strategic Insights (2025–2033) The Global Sepsis Treat ...

Gen Z's preference for convenient formats like gummies and effervescent powders, coupled with rising health awareness, is ...

The presented data provides a snapshot of the financial health and recent market performance of key stocks within the NIFTY MIDCAP 150 index.

U.S. Senator Maggie Hassan has initiated an investigation into GlaxoSmithKline's decision to discontinue the Flovent HFA ...

GlaxoSmithKline Pharmaceuticals, with its shares currently priced at Rs 3,292.30, remains a key stock to watch, particularly for those invested in or tracking the NIFTY MIDCAP 150 index.

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Senator Maggie Hassan launches an investigation into GlaxoSmithKline's withdrawal of a popular asthma inhaler, linking it to ...

After years of collecting consumer DNA, genetic testing companies are monetizing the data. But who should profit — the ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on June 24 and set a price target of £14.50. The company’s shares ...

Stay updated with the latest stock market news and live updates. Get real-time insights on Sensex Today, Nifty Live, stock market today, IPO news and more on Business Standard.

Hassan cited a Johns Hopkins analysis which found that GSK's move saved the company $367 million in 2024 Medicaid rebates, ...